165 related articles for article (PubMed ID: 11393754)
1. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields.
Lindegren S; Bäck T; Jensen HJ
Appl Radiat Isot; 2001 Aug; 55(2):157-60. PubMed ID: 11393754
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction.
Larsen RH; Wieland BW; Zalutsky MR
Appl Radiat Isot; 1996 Feb; 47(2):135-43. PubMed ID: 8852627
[TBL] [Abstract][Full Text] [Related]
3. Production of (211)At by a vertical beam irradiation method.
Nagatsu K; Minegishi K; Fukada M; Suzuki H; Hasegawa S; Zhang MR
Appl Radiat Isot; 2014 Dec; 94():363-371. PubMed ID: 25439168
[TBL] [Abstract][Full Text] [Related]
4. Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets.
Schwarz UP; Plascjak P; Beitzel MP; Gansow OA; Eckelman WC; Waldmann TA
Nucl Med Biol; 1998 Feb; 25(2):89-93. PubMed ID: 9468021
[TBL] [Abstract][Full Text] [Related]
5. Behaviour, use and safety aspects of astatine-211 solvated in chloroform after dry distillation recovery.
Aneheim E; Hansson E; Timperanza C; Jensen H; Lindegren S
Sci Rep; 2024 Apr; 14(1):9698. PubMed ID: 38678056
[TBL] [Abstract][Full Text] [Related]
6. Optimisation of cyclotron production parameters for the 209Bi(alpha, 2n) 211At reaction related to biomedical use of 211At.
Henriksen G; Messelt S; Olsen E; Larsen RH
Appl Radiat Isot; 2001 May; 54(5):839-44. PubMed ID: 11258534
[TBL] [Abstract][Full Text] [Related]
7. Towards elucidating the radiochemistry of astatine - Behavior in chloroform.
Aneheim E; Palm S; Jensen H; Ekberg C; Albertsson P; Lindegren S
Sci Rep; 2019 Nov; 9(1):15900. PubMed ID: 31685874
[TBL] [Abstract][Full Text] [Related]
8. Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.
Wilbur DS; Hamlin DK; Chyan MK; Brechbiel MW
Bioconjug Chem; 2008 Jan; 19(1):158-70. PubMed ID: 18072725
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of thiosemicarbazide in Amberlite IRC-50 for separation of astatine from alpha-irradiated bismuth oxide.
Roy K; Basu S; Ramaswami A; Nayak D; Lahiri S
Appl Radiat Isot; 2004 Jun; 60(6):793-9. PubMed ID: 15110342
[TBL] [Abstract][Full Text] [Related]
10. Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.
Lindegren S; Albertsson P; Bäck T; Jensen H; Palm S; Aneheim E
Cancer Biother Radiopharm; 2020 Aug; 35(6):425-436. PubMed ID: 32077749
[TBL] [Abstract][Full Text] [Related]
11. Production, isolation, and shipment of clinically relevant quantities of astatine-211: A simple and efficient approach to increasing supply.
McIntosh LA; Burns JD; Tereshatov EE; Muzzioli R; Hagel K; Jinadu NA; McCann LA; Picayo GA; Pisaneschi F; Piwnica-Worms D; Schultz SJ; Tabacaru GC; Abbott A; Green B; Hankins T; Hannaman A; Harvey B; Lofton K; Rider R; Sorensen M; Tabacaru A; Tobin Z; Yennello SJ
Nucl Med Biol; 2023; 126-127():108387. PubMed ID: 37837782
[TBL] [Abstract][Full Text] [Related]
12. Production of α-particle emitting ²¹¹At using 45 MeV α-beam.
Kim G; Chun K; Park SH; Kim B
Phys Med Biol; 2014 Jun; 59(11):2849-60. PubMed ID: 24819557
[TBL] [Abstract][Full Text] [Related]
13. Astatine-211: production and availability.
Zalutsky MR; Pruszynski M
Curr Radiopharm; 2011 Jul; 4(3):177-85. PubMed ID: 22201707
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.
Radchenko V; Schaffer P; Knapp FFR
Curr Radiopharm; 2018; 11(3):154-155. PubMed ID: 30378473
[No Abstract] [Full Text] [Related]
15. Development of a preclinical
Crawford JR; Yang H; Kunz P; Wilbur DS; Schaffer P; Ruth TJ
Nucl Med Biol; 2017 May; 48():31-35. PubMed ID: 28193502
[TBL] [Abstract][Full Text] [Related]
16. Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.
Aneheim E; Albertsson P; Bäck T; Jensen H; Palm S; Lindegren S
Sci Rep; 2015 Jul; 5():12025. PubMed ID: 26169786
[TBL] [Abstract][Full Text] [Related]
17. A new internal target system for production of (211)At on the cyclotron U-120M.
Lebeda O; Jiran R; Rális J; Stursa J
Appl Radiat Isot; 2005 Jul; 63(1):49-53. PubMed ID: 15866447
[TBL] [Abstract][Full Text] [Related]
18. Proton-induced production and radiochemical isolation of
Radchenko V; Engle JW; Medvedev DG; Maassen JM; Naranjo CM; Unc GA; Meyer CAL; Mastren T; Brugh M; Mausner L; Cutler CS; Birnbaum ER; John KD; Nortier FM; Fassbender ME
Nucl Med Biol; 2017 Jul; 50():25-32. PubMed ID: 28432915
[TBL] [Abstract][Full Text] [Related]
19. A kit method for the high level synthesis of [211At]MABG.
Vaidyanathan G; Affleck DJ; Alston KL; Zhao XG; Hens M; Hunter DH; Babich J; Zalutsky MR
Bioorg Med Chem; 2007 May; 15(10):3430-6. PubMed ID: 17387017
[TBL] [Abstract][Full Text] [Related]
20. Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells.
Orlova A; Sjöstrom A; Lebeda O; Lundqvist H; Carlsson J; Tolmachev V
Anticancer Res; 2004; 24(6):4035-41. PubMed ID: 15736449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
